Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines

Bibliography

• Mackiewicz J, Mackiewicz A. Immunotherapy of cancer and perspectives of its development. Wspolczesna Onkol Contemporary Oncol 2010;14:59-71
   Web of Science ®Google Scholar
• Majidi J, Barar J, Baradaran B, Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009;18:81-100
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-9
   PubMed Web of Science ®Google Scholar
• Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155-61
   PubMed Web of Science ®Google Scholar
• Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010;22:144-54
   PubMed Web of Science ®Google Scholar
• Chabalgoity JA, Baz A, Rial A, Grille S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 2007;18:195-207
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC. 18991, a randomised phase III trial. Lancet 2008;372:117-26
   PubMed Web of Science ®Google Scholar
• Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009;100:1389-96
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Muller-Newen G, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314
   PubMed Web of Science ®Google Scholar
• Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997;89:3897-908
   PubMed Web of Science ®Google Scholar
• Dams-Kozlowska H, Izycki D, Mackiewicz A. IL-11 is a potent anti-melanoma factor. Adv Exp Med Biol 2001;495:373-7
   PubMed Web of Science ®Google Scholar
• Baumann H, Wang Y, Morella KK, Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J Immunol 1996;157:284-90
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Dams-Kozlowska H, Rose-John S. Chimeric soluble Hyper-IL-11 and use thereof. WO2005113591; 2005
   Google Scholar
• Jocham D, Richter A, Hoffmann L, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-9
   PubMed Web of Science ®Google Scholar
• Bernhard H, Lohmann M, Batten WY, The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp Hematol 2000;28:365-72
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-7
   PubMed Web of Science ®Google Scholar
• Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods 2001;253:163-75
   PubMed Web of Science ®Google Scholar
• Evenson TC, Cole WH. Spontaneous Regression of Cancer. W.B. Saunders; Philadelphia: 1996. p. 11-87
   Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther 2007;7:727-37
   PubMed Web of Science ®Google Scholar
• Wilmanns C, Fan D, O'Brian CA, Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992;52:98-104
   PubMed Web of Science ®Google Scholar
• Ahn KS, Jung YS, Kim J, Behavior of murine renal carcinoma cells grown in ectopic or orthotopic sites in syngeneic mice. Tumour Biol 2001;22:146-53
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Mackiewicz A. Gene-modified cellular vaccines: technologic aspects and clinical problems. Transplant Proc 2010;42:3287-92
   PubMed Web of Science ®Google Scholar
• Jongmans W, van den Oudenalder K, Tiemessen DM, Targeting of adenovirus to human renal cell carcinoma cells. Urology 2003;62:559-65
   PubMed Web of Science ®Google Scholar
• Yang ZR, Wang HF, Zhao J, Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 2007;14:599-615
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Kazimierczak U, Suchorska W, Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther 2010;17:465-75
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res 2006;12:4095-102
   PubMed Web of Science ®Google Scholar
• Alderson KL, Murphy WJ. Antigen specific memory T cells and their putative need for the generation of sustained anti-tumor responses. Adv Exp Med Biol 2010;684:155-65
   PubMed Web of Science ®Google Scholar
• Westwood JA, Darcy PK, Guru PM, Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 2010;8:42
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20
   PubMed Web of Science ®Google Scholar
• Gaillard J, Pugniere M, Tresca J, Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. Eur Cytokine Netw 1999;10:337-44
   PubMed Web of Science ®Google Scholar
• Curtis DJ, Hilton DJ, Roberts B, Recombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist. Blood 1997;90:4403-12
   PubMed Web of Science ®Google Scholar
• Fischer M, Goldschmitt J, Peschel C, A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997;15:142-5
   PubMed Web of Science ®Google Scholar
• Pflanz S, Tacken I, Grotzinger J, A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett 1999;450:117-22
   PubMed Web of Science ®Google Scholar
• Dominitzki S, Fantini MC, Neufert C, Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007;179:2041-5
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J, Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-33
   PubMed Web of Science ®Google Scholar
• Mills KH. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunol Lett 2009;122:108-11
   PubMed Web of Science ®Google Scholar
• Casares N, Arribillaga L, Sarobe P, CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171:5931-9
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229-38
   PubMed Web of Science ®Google Scholar
• Terme M, Chaput N, Combadiere B, Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol 2008;180:4679-86
   PubMed Web of Science ®Google Scholar
• Teng MW, Swann JB, von Scheidt B, Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010;70:2665-74
   PubMed Web of Science ®Google Scholar
• Drakesmith H, O'Neil D, Schneider SC, In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc Natl Acad Sci USA 1998;95:14903-8
   PubMed Web of Science ®Google Scholar
• Ozbek S, Peters M, Breuhahn K, The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001;20:972-9
   PubMed Web of Science ®Google Scholar
• Driessens G, Hoffmann P, Pouwels M, Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. J Immunother 2009;32:140-4
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Laciak M, Izycki D, Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Adv Exp Med Biol 2001;495:411-18
   PubMed Web of Science ®Google Scholar
• Izycki D, Nawrocki S, Laciak M, Effect of cyclophosphamide on tumorogenesis of the IL-6 and Hyper-IL-6 gene modified murine melanoma cells. Wspolczesna Onkol Contemporary Oncol 2004;8:124-31
   Google Scholar
• Nawrocki S, Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert Opin Investig Drugs 2007;16:1137-41
   PubMed Web of Science ®Google Scholar
• Basak GW, Zapala L, Wysocki PJ, Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol Rep 2008;19:1173-9
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. The synergistic effect of cytokines at gene therapy of murine melanoma. PhD Thesis 2000.
   Google Scholar